全阻断胃窦癌根治术预防癌转移

2012-11-16 Jane摘编 中国实用外科杂志

  复旦大学附属华山医院普外科的一项研究表明,全阻断胃窦癌根治术可以有效地阻断术中癌细胞血行和淋巴转移。该论文发表在2012年第10期《中国实用外科杂志》。     该研究选取2008 年7 月至2010 年9 月收治的76例胃窦癌病人,随机分为两组,分别施行全阻断胃窦癌根治术(阻断组)和传统胃癌根治术(常规组),进腹后及术中分别抽取门静脉血和腹腔灌洗液,

  复旦大学附属华山医院普外科的一项研究表明,全阻断胃窦癌根治术可以有效地阻断术中癌细胞血行和淋巴转移。该论文发表在2012年第10期《中国实用外科杂志》。  

  该研究选取2008 年7 月至2010 年9 月收治的76例胃窦癌病人,随机分为两组,分别施行全阻断胃窦癌根治术(阻断组)和传统胃癌根治术(常规组),进腹后及术中分别抽取门静脉血和腹腔灌洗液,RT-PCR测定样本中CEA mRNA和CK20 mRNA的表达情况;阻断组胃壁注射纳米炭后观察阻断区内外淋巴结有无黑染。

  结果显示,进腹后,阻断组门静脉血CEA mRNA和CK20 mRNA阳性率分别为10%和15%,常规组为8.3%和11.1%,两组差异无统计学意义;术中牵拉胃癌病灶时,阻断组门静脉血CEA mRNA和CK20 mRNA的阳性率分别为7.5%和15%,常规组为30.5%和36%,两组差异具有统计学意义(P<0.05);腹腔灌洗液CEA mRNA和CK20 mRNA的表达率差异无统计学意义。阻断区内淋巴结明显黑染,而阻断区外无淋巴结黑染。



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1709968, encodeId=fed71e0996835, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sat Feb 02 15:07:00 CST 2013, time=2013-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399702, encodeId=e4b81399e02f8, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487976, encodeId=3e29148e9763b, content=<a href='/topic/show?id=5c699e46010' target=_blank style='color:#2F92EE;'>#防癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97460, encryptionId=5c699e46010, topicName=防癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6d78400961, createdName=jeanqiuqiu, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586000, encodeId=4cf0158600082, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590235, encodeId=a88a1590235fb, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1709968, encodeId=fed71e0996835, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sat Feb 02 15:07:00 CST 2013, time=2013-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399702, encodeId=e4b81399e02f8, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487976, encodeId=3e29148e9763b, content=<a href='/topic/show?id=5c699e46010' target=_blank style='color:#2F92EE;'>#防癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97460, encryptionId=5c699e46010, topicName=防癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6d78400961, createdName=jeanqiuqiu, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586000, encodeId=4cf0158600082, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590235, encodeId=a88a1590235fb, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1709968, encodeId=fed71e0996835, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sat Feb 02 15:07:00 CST 2013, time=2013-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399702, encodeId=e4b81399e02f8, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487976, encodeId=3e29148e9763b, content=<a href='/topic/show?id=5c699e46010' target=_blank style='color:#2F92EE;'>#防癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97460, encryptionId=5c699e46010, topicName=防癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6d78400961, createdName=jeanqiuqiu, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586000, encodeId=4cf0158600082, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590235, encodeId=a88a1590235fb, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=)]
    2012-11-18 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1709968, encodeId=fed71e0996835, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sat Feb 02 15:07:00 CST 2013, time=2013-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399702, encodeId=e4b81399e02f8, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487976, encodeId=3e29148e9763b, content=<a href='/topic/show?id=5c699e46010' target=_blank style='color:#2F92EE;'>#防癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97460, encryptionId=5c699e46010, topicName=防癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6d78400961, createdName=jeanqiuqiu, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586000, encodeId=4cf0158600082, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590235, encodeId=a88a1590235fb, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=)]
    2012-11-18 jeanqiuqiu
  5. [GetPortalCommentsPageByObjectIdResponse(id=1709968, encodeId=fed71e0996835, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sat Feb 02 15:07:00 CST 2013, time=2013-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399702, encodeId=e4b81399e02f8, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487976, encodeId=3e29148e9763b, content=<a href='/topic/show?id=5c699e46010' target=_blank style='color:#2F92EE;'>#防癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97460, encryptionId=5c699e46010, topicName=防癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6d78400961, createdName=jeanqiuqiu, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586000, encodeId=4cf0158600082, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590235, encodeId=a88a1590235fb, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=)]

相关资讯

胃肠道恶性淋巴瘤确诊率低

  《中国普通外科杂志》的一项研究显示,原发性胃肠道恶性淋巴瘤术前确诊率低,胃肠镜及病理活检是术前确诊的主要方法,以手术化疗联合的综合治疗效果良好。该论文发表在2012年第4期。   该研究回顾性分析1995年1月—2010年12月间34例原发性胃肠道恶性淋巴瘤患者临床资料。男23例,女11例,平均年龄51.8岁。   患者均经病理证实为恶性淋巴瘤,原发病灶位于胃24例,肠道10例

术前同步放化疗:直肠癌的标准治疗模式

       中国医学科学院肿瘤医院放疗科 任骅 金晶 王鑫 王维虎 李晔雄        直肠癌根治术后同步放化疗研究        可切除Ⅱ~Ⅲ期直肠癌根治术后的局部区域复发率为15%~65%,即使行全直肠系膜切除术(TME),Ⅲ期患者的局部区域复发率仍可达20%~3

手辅助腹腔镜手术降低是手术难度

  浙江大学医学院附属第一医院肛肠外科刘凡隆、盛勤松等的一项研究显示,手辅助腹腔镜直肠癌根治术在保留微创优势的同时降低了手术难度,安全可靠,快速微创,具有广阔的临床应用前景。该论文发表在2012年第7期《中华外科杂志》。   研究者回顾性分析了2009年8月至2011年4月行手辅助腹腔镜直肠癌根治术156例患者的临床资料,分析手术效果及术后并发症情况。   结果显示,156例患者均顺利完成手术